对REP9AC、DV601等治愈乙肝科学研究的看法

StephenW

回复 kaorusai 的帖子

"请大家来拍砖讨论" -
http://www.hbvhbv.com/forum/thread-1067454-1-1.html
http://www.hbvhbv.com/forum/thread-1066205-1-1.html

这是从Replicor的CEO:
We are still very enthousiastic about REP 9AC's potential to achieve sustained virologic response in patients with chronic hepatitis B. Our current SVR rate is at 50 %.

The next time we will release data about our clinical trial will be during the AASLD meeting in San Francisco in November 2011"

"Is it possible to say how many years?"

"Probably 3 to 4 years. This is just an estimate...."              

走遍四方

Our current SVR rate is at 50 %.

kaorusai

回复 StephenW 的帖子

这些信息很有用！谢谢
治愈型疫苗的确很不靠谱.....
REP9AC 治愈率不到50%，太低了，这个专家说要开发什么联合治疗的提高SVR吧

CEO居然说估计3、4年能上市吧...以现在的治愈率恐怕很难..


难道我们只有寄希望于RNAI技术的成熟？

StephenW

kaorusai 发表于 2011-9-5 14:49
回复 StephenW 的帖子

这些信息很有用！谢谢

据studyforhope，未来最有可能
是组合治疗。最主要的是更多的临床试验。理论无法预测一切。

StephenW

kaorusai 发表于 2011-9-5 14:16
"其中有一人DNA复制降不下来" - (05B)不完全同意, 下降但不为0.-----指的是05B,没降到正常值，有待观察吧
" ...

02B - ALT, HbsAg是相当不错的.

"不知道为什么表面抗原降下来,DNA还在复制，我不是专家，真不清楚 " -
据studyforhope，REP9AC停止乙肝表面抗原包覆颗粒（非感染）的形成和释放，而不停止新病毒颗粒的生产和释放. 要停止DNA复制, 可以用antivirals.

kaorusai

回复 StephenW 的帖子

02B - ALT, HbsAg是相当不错的.------------我也觉得相当不错了

治疗乙肝并不要求完全治愈，只要控制病情能够保证不复发目的就达到了

StephenW

Dr. Mamun-Al-Mahtab医生是主管Rep9AC的临床试验.

"As the General Secretary of the Organizing Committee, I am pleased to inform you that Association for the Study of the Liver, Dhaka, Bangladesh (ASLDB) - the national Association of Hepatologists of the country, is going to organize the APASL 3rd STC on HBV Dhaka, Bangladesh from December 7 to, 2012. Your active participation is most vital in making this biggest even of Hepatology in Bangladesh a success and will surely go a long way in furthering Hepatology in this country.

On behalf of the Association members, I request your active participation in this meeting. Please mark the dates in your calender in advance, circulate this information among your friends and colleagues and encourage all to submit abstracts to the meeting.

We promise you some memorable times in Dhaka!

Thanking you.
Kind regards,

Dr. Mamun-Al-Mahtab (www.drmahtab.org)
Editor, LIVER: A Complete Book on Hepato-Pancreato-Biliary Diseases
Editor, Comprehensive Text Book of Hepatitis B
Secretary General, Association for the Study of the Liver, Dhaka, Bangladesh
Secretary General,Viral Hepatitis Foundation Bangladesh
Assistant Professor of Hepatology, Bangabandhu Sheikh Mujib Medical University
Deputy Editor-in-Chief, Euroasian Journal of Hepato-Gastroenterology
Deputy Editor-in-Chief, Clinical and Experimental Medical Journal
Editorial Board Member, Journal of Clinical and Experimental Hepatology
Journal of Global Infectious Diseases, Hepatitis Monthly, Microbiology Research  

hoimes

关键是表面抗体的出现机率，有5个人出现了，但不幸的是有人（2人）表抗又阴转了，说明体内病毒复制数量很大未得到抑制。我想进入临床时，应结合核苷类药物，先把DNA转阴，病毒负荷降到最低，然后再使用REP9ac，一举完全消灭病毒，同时由于病毒载荷低，引起的免疫反应不致过于激烈。傻瓜才会使用单一药物吧。

hoimes

再补充一点，最后两个之治疗了13周，而前6个人有5人表面抗原阴转，现在所有药物治疗一年表面抗原转阴的概率不高于1%，楼主的分析太粗了。

kaorusai

StephenW 发表于 2011-9-5 17:38
Dr. Mamun-Al-Mahtab医生是主管Rep9AC的临床试验.

"As the General Secretary of the Organizing Committe ...

我的英语能力很糟糕....